EUVIMEDEUVIMED entdecken
Open Access

Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective

Dirk Mehrens iD, Matthias P Fabritius iD, Paul Reidler, Thomas Liebig, Saif Afat, Johanna M Ospel iD, Matthias F Fröhlich, Julian Schwarting iD, Jens Ricke, Konstantinos Dimitriadis, Mayank Goyal, Wolfgang G Kunz

European Stroke Journal · 2024

DOI: 10.1177/23969873231209616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Stroke Journal, 2024. Verfasst von Dirk Mehrens und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Basilar Artery, Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Two recent studies showed clinical benefit for endovascular treatment (EVT) in basilar artery occlusion (BAO) stroke up to 12 h (ATTENTION) and between 6 and 24 h from onset (BAOCHE). Our aim was to investigate the cost-effectiveness of EVT from a U.S. healthcare perspective. Materials and Methods: Clinical input data were available for both trials, which were analyzed separately. A decision model was built consisting of a short-run model to analyze costs and functional outcomes within 90 days after the index stroke and a long-run Markov state transition model (cycle length of 12 months) to estimate expected lifetime costs and outcomes from a healthcare and a societal perspective. Incremental cost-effectiveness ratios (ICER) were calculated, deterministic (DSA) and probabilistic (PSA) sensitivity analyses were performed.

Results

EVT in addition to best medical management (BMM) resulted in additional lifetime costs of $32,063 in the ATTENTION trial and lifetime cost savings of $7690 in the BAOCHE trial (societal perspective). From a healthcare perspective, EVT led to incremental costs and effectiveness of $37,389 and 2.0 QALYs (ATTENTION) as well as $3516 and 1.9 QALYs (BAOCHE), compared to BMM alone. The ICER values were $−4052/QALY (BAOCHE) and $15,867/QALY (ATTENTION) from a societal perspective. In each trial, PSA showed EVT to be cost-effective in most calculations (99.9%) for a willingness-to-pay threshold of $100,000/QALY. Cost of EVT and age at stroke represented the greatest impact on the ICER.

Discussion

From an economic standpoint with a lifetime horizon, EVT in addition to BMM is estimated to be highly effective and cost-effective in BAO stroke.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basilar ArteryStrokeHumansClinical Trials as TopicCost-Benefit AnalysisDelivery of Health Care

Stichwörter der Autor:innen

Thrombectomybasilar artery occlusioncost-effectivenessischemic stroke

Autor:innen und Institutionen

  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Radiology, University of Tübingen, Tübingen, Germany.
  • Departments of Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
  • Department of Radiology, University Hospital of Basel, Basel, Switzerland.
  • Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.

ORCID-Profile: Dirk Mehrens, Matthias P Fabritius, Johanna M Ospel, Julian Schwarting

Zitieren

APA

Mehrens, D., Fabritius, M. P., Reidler, P., Liebig, T., Afat, S., Ospel, J. M., Fröhlich, M. F., Schwarting, J., Ricke, J., Dimitriadis, K., Goyal, M., & Kunz, W. G. (2024). Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective. European Stroke Journal. https://doi.org/10.1177/23969873231209616

Vancouver

Mehrens D, Fabritius MP, Reidler P, Liebig T, Afat S, Ospel JM, et al. Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective. European Stroke Journal. 2024. doi:10.1177/23969873231209616

BibTeX
@article{Mehrens2024,
  author = {Mehrens, Dirk and Fabritius, Matthias P and Reidler, Paul and Liebig, Thomas and Afat, Saif and Ospel, Johanna M and Fröhlich, Matthias F and Schwarting, Julian and Ricke, Jens and Dimitriadis, Konstantinos and Goyal, Mayank and Kunz, Wolfgang G},
  title = {Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective},
  journal = {European Stroke Journal},
  year = {2024},
  doi = {10.1177/23969873231209616}
}
Kostenlos starten →